227 related articles for article (PubMed ID: 10477295)
1. Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass.
Filvaroff E; Erlebacher A; Ye J; Gitelman SE; Lotz J; Heillman M; Derynck R
Development; 1999 Oct; 126(19):4267-79. PubMed ID: 10477295
[TBL] [Abstract][Full Text] [Related]
2. Osteoblastic responses to TGF-beta during bone remodeling.
Erlebacher A; Filvaroff EH; Ye JQ; Derynck R
Mol Biol Cell; 1998 Jul; 9(7):1903-18. PubMed ID: 9658179
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype.
Erlebacher A; Derynck R
J Cell Biol; 1996 Jan; 132(1-2):195-210. PubMed ID: 8567723
[TBL] [Abstract][Full Text] [Related]
4. Impaired bone formation in transgenic mice resulting from altered integrin function in osteoblasts.
Zimmerman D; Jin F; Leboy P; Hardy S; Damsky C
Dev Biol; 2000 Apr; 220(1):2-15. PubMed ID: 10720426
[TBL] [Abstract][Full Text] [Related]
5. Transgenic Expression of Osteoactivin/gpnmb Enhances Bone Formation In Vivo and Osteoprogenitor Differentiation Ex Vivo.
Frara N; Abdelmagid SM; Sondag GR; Moussa FM; Yingling VR; Owen TA; Popoff SN; Barbe MF; Safadi FF
J Cell Physiol; 2016 Jan; 231(1):72-83. PubMed ID: 25899717
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone.
Mohammad KS; Chen CG; Balooch G; Stebbins E; McKenna CR; Davis H; Niewolna M; Peng XH; Nguyen DH; Ionova-Martin SS; Bracey JW; Hogue WR; Wong DH; Ritchie RO; Suva LJ; Derynck R; Guise TA; Alliston T
PLoS One; 2009; 4(4):e5275. PubMed ID: 19357790
[TBL] [Abstract][Full Text] [Related]
7. In vivo inhibition of osteoblastic metalloproteinases leads to increased trabecular bone mass.
Geoffroy V; Marty-Morieux C; Le Goupil N; Clement-Lacroix P; Terraz C; Frain M; Roux S; Rossert J; de Vernejoul MC
J Bone Miner Res; 2004 May; 19(5):811-22. PubMed ID: 15068505
[TBL] [Abstract][Full Text] [Related]
8. Osteoblast menin regulates bone mass in vivo.
Kanazawa I; Canaff L; Abi Rafeh J; Angrula A; Li J; Riddle RC; Boraschi-Diaz I; Komarova SV; Clemens TL; Murshed M; Hendy GN
J Biol Chem; 2015 Feb; 290(7):3910-24. PubMed ID: 25538250
[TBL] [Abstract][Full Text] [Related]
9. Effect of osteoblast-targeted expression of bcl-2 in bone: differential response in male and female mice.
Pantschenko AG; Zhang W; Nahounou M; McCarthy MB; Stover ML; Lichtler AC; Clark SH; Gronowicz GA
J Bone Miner Res; 2005 Aug; 20(8):1414-29. PubMed ID: 16007339
[TBL] [Abstract][Full Text] [Related]
10. Mutation in osteoactivin decreases bone formation in vivo and osteoblast differentiation in vitro.
Abdelmagid SM; Belcher JY; Moussa FM; Lababidi SL; Sondag GR; Novak KM; Sanyurah AS; Frara NA; Razmpour R; Del Carpio-Cano FE; Safadi FF
Am J Pathol; 2014 Mar; 184(3):697-713. PubMed ID: 24462663
[TBL] [Abstract][Full Text] [Related]
11. Deficiency of the G-protein alpha-subunit G(s)alpha in osteoblasts leads to differential effects on trabecular and cortical bone.
Sakamoto A; Chen M; Nakamura T; Xie T; Karsenty G; Weinstein LS
J Biol Chem; 2005 Jun; 280(22):21369-75. PubMed ID: 15797856
[TBL] [Abstract][Full Text] [Related]
12. Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss.
Wang L; Liu S; Quarles LD; Spurney RF
Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E826-34. PubMed ID: 15585587
[TBL] [Abstract][Full Text] [Related]
13. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.
Rhodes SD; Wu X; He Y; Chen S; Yang H; Staser KW; Wang J; Zhang P; Jiang C; Yokota H; Dong R; Peng X; Yang X; Murthy S; Azhar M; Mohammad KS; Xu M; Guise TA; Yang FC
J Bone Miner Res; 2013 Dec; 28(12):2476-89. PubMed ID: 23703870
[TBL] [Abstract][Full Text] [Related]
14. E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-β in the bone microenvironment.
Yang T; Grafe I; Bae Y; Chen S; Chen Y; Bertin TK; Jiang MM; Ambrose CG; Lee B
Proc Natl Acad Sci U S A; 2013 Apr; 110(18):7336-41. PubMed ID: 23589896
[TBL] [Abstract][Full Text] [Related]
15. The Rho-GEF Kalirin regulates bone mass and the function of osteoblasts and osteoclasts.
Huang S; Eleniste PP; Wayakanon K; Mandela P; Eipper BA; Mains RE; Allen MR; Bruzzaniti A
Bone; 2014 Mar; 60():235-45. PubMed ID: 24380811
[TBL] [Abstract][Full Text] [Related]
16. Skeletal characterization of an osteoblast-specific vitamin D receptor transgenic (ObVDR-B6) mouse model.
Triliana R; Lam NN; Sawyer RK; Atkins GJ; Morris HA; Anderson PH
J Steroid Biochem Mol Biol; 2016 Nov; 164():331-336. PubMed ID: 26343450
[TBL] [Abstract][Full Text] [Related]
17. Osteoclast TGF-β Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation.
Weivoda MM; Ruan M; Pederson L; Hachfeld C; Davey RA; Zajac JD; Westendorf JJ; Khosla S; Oursler MJ
J Bone Miner Res; 2016 Jan; 31(1):76-85. PubMed ID: 26108893
[TBL] [Abstract][Full Text] [Related]
18. Constitutive protein kinase A activity in osteocytes and late osteoblasts produces an anabolic effect on bone.
Kao RS; Abbott MJ; Louie A; O'Carroll D; Lu W; Nissenson R
Bone; 2013 Aug; 55(2):277-87. PubMed ID: 23583750
[TBL] [Abstract][Full Text] [Related]
19. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.
Okamoto M; Murai J; Yoshikawa H; Tsumaki N
J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523
[TBL] [Abstract][Full Text] [Related]
20. Osteocyte- and late osteoblast-derived NOTUM reduces cortical bone mass in mice.
Nilsson KH; Henning P; El Shahawy M; Wu J; Koskela A; Tuukkanen J; Perret C; Lerner UH; Ohlsson C; Movérare-Skrtic S
Am J Physiol Endocrinol Metab; 2021 May; 320(5):E967-E975. PubMed ID: 33749332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
